Wright Medical Enters Injectable BVF Market, Joining J&J/DePuy, Synthes
This article was originally published in The Gray Sheet
Executive Summary
Wright Medical Group will market its MIIG 115 minimally invasive injectable Osteoset bone graft substitute system primarily to trauma surgeons supported by a sales force of 220 commissioned reps in the U.S
You may also be interested in...
Wright Medical Planning Lineage Ceramic-On-Ceramic Hip Launch In Q4
Wright Medical and Stryker Howmedica Osteonics are both awaiting ceramic material supplier GMP certification prior to final FDA approval for their respective Lineage and Trident ceramic-on-ceramic hip prostheses, expected in late 2002
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”